S&P 500
(-0.21%) 5 051.41 points
Dow Jones
(0.17%) 37 799 points
Nasdaq
(-0.12%) 15 865 points
Oil
(-0.15%) $85.28
Gas
(-0.65%) $1.680
Gold
(0.68%) $2 399.20
Silver
(-1.84%) $28.19
Platinum
(-1.07%) $970.50
USD/EUR
(0.05%) $0.942
USD/NOK
(0.43%) $10.98
USD/GBP
(0.11%) $0.804
USD/RUB
(0.70%) $94.16

Realtime updates for Hikma Pharmaceuticals PLC [HKMPY]

Exchange: OTC Sector: Healthcare Industry: Drug Manufacturersā€”Specialty & Generic
Last Updated15 Apr 2024 @ 10:33

0.00% $ 46.50

Live Chart Being Loaded With Signals

Commentary (15 Apr 2024 @ 10:33):

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms...

Stats
Today's Volume 2.00
Average Volume 174.00
Market Cap 5.16B
Last Dividend $0.500 ( 2023-08-11 )
Next Dividend $0 ( N/A )
P/E 27.35
ATR14 $0 (0.00%)

Hikma Pharmaceuticals PLC Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Hikma Pharmaceuticals PLC Financials

Annual 2023
Revenue: $2.88B
Gross Profit: $1.39B (48.35 %)
EPS: $1.720
Q4 2023
Revenue: $1.44B
Gross Profit: $623.01M (43.37 %)
EPS: $0.530
Q2 2023
Revenue: $1.43B
Gross Profit: $690.00M (48.35 %)
EPS: $1.190
Q4 2022
Revenue: $1.37B
Gross Profit: $622.03M (45.48 %)
EPS: $0.140

Financial Reports:

No articles found.

Hikma Pharmaceuticals PLC Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.380
(N/A)
$0
(N/A)
$0.740
(N/A)
$0
(N/A)
$0.500
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Hikma Pharmaceuticals PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.94 - Stable (1.18%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.150 2012-04-18
Last Dividend $0.500 2023-08-11
Next Dividend $0 N/A
Payout Date 2023-09-25
Next Payout Date N/A
# dividends 24 --
Total Paid Out $8.89 --
Avg. Dividend % Per Year 0.00% --
Score 3.65 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.94
Div. Directional Score 8.03 --
Next Divdend (Est)
(2024-06-21)
$0.505 Estimate 7.56 %
Dividend Stability
0.30 Poor
Dividend Score
3.65
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
TTNDF Ex Dividend Knight 2023-08-29 Annually 0 0.00%
KAEPF Ex Dividend Junior 2023-09-28 Annually 0 0.00%
CDEVY Ex Dividend Knight 2023-08-22 Semi-Annually 0 0.00%
RNMBY Ex Dividend Knight 2023-05-10 Annually 0 0.00%
FNFI Ex Dividend Knight 2023-09-07 Quarterly 0 0.00%
AHCHY Ex Dividend Junior 2023-06-01 Annually 0 0.00%
VNRFY Ex Dividend Junior 2023-05-30 Annually 0 0.00%
MALRY Ex Dividend Junior 2023-09-07 Annually 0 0.00%
CNLPM Ex Dividend Knight 2023-07-07 Quarterly 0 0.00%
SKLTY Ex Dividend Junior 2023-09-05 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06621.5008.6810.00[0 - 0.5]
returnOnAssetsTTM0.04051.2008.6510.00[0 - 0.3]
returnOnEquityTTM0.08641.500-0.151-0.227[0.1 - 1]
payoutRatioTTM0.717-1.0002.83-2.83[0 - 1]
currentRatioTTM1.5680.8007.165.73[1 - 3]
quickRatioTTM0.8900.8009.477.58[0.8 - 2.5]
cashRatioTTM0.1531.500-0.261-0.391[0.2 - 2]
debtRatioTTM0.254-1.5005.76-8.64[0 - 0.6]
interestCoverageTTM5.461.0009.099.09[3 - 30]
operatingCashFlowPerShareTTM4.792.008.4010.00[0 - 30]
freeCashFlowPerShareTTM2.962.008.5210.00[0 - 20]
debtEquityRatioTTM0.542-1.5007.83-10.00[0 - 2.5]
grossProfitMarginTTM0.4591.0005.695.69[0.2 - 0.8]
operatingProfitMarginTTM0.1651.0008.708.70[0.1 - 0.6]
cashFlowToDebtRatioTTM0.4441.0008.648.64[0.2 - 2]
assetTurnoverTTM0.6120.8009.257.40[0.5 - 2]
Total Score11.12

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM27.421.0007.330[1 - 100]
returnOnEquityTTM0.08642.50-0.0971-0.227[0.1 - 1.5]
freeCashFlowPerShareTTM2.962.009.0110.00[0 - 30]
dividendYielPercentageTTM3.011.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM4.792.008.4010.00[0 - 30]
payoutRatioTTM0.7171.5002.83-2.83[0 - 1]
pegRatioTTM1.9811.5000.1300[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1851.0007.880[0.1 - 0.5]
Total Score4.94

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators